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Abstract
Surfactants are amphipathic substances with lyophobic and lyophilic groups and 
are critical components in pharmaceutical products. Surfactants have several uses 
in pharmaceuticals, i) for solubilisation of hydrophobic drugs in aqueous media, 
ii) as components of emulsions ,iii) surfactant self-assembly vehicles for oral and 
transdermal drug delivery, iv) as plasticizers in semisolid delivery systems, and v) as 
agents to improve drug absorption and penetration. Non-ionic surfactants such as ethers 
of fatty alcohols are most commonly used in pharmaceuticals. Cationic surfactants are 
capable of exerting antibacterial properties by disrupting bacterial cell membranes. 
In pharmaceutical processing, phospholipid lecithin, bile salts, certain fatty acids and 
their derivatives have become indispensable since they afford a uniquely effective and 
efficient mechanism of drug carriage by solubilising the drugs of fatty origin. The 
antibacterial, antifungal and antiviral activities make biosurfactants relevant molecules 
for applications in combating many diseases and as therapeutic agents. Biosurfactants 
have the potential for use as major immunomodulatory molecules, as anti-adhesive 
biological coating for biomaterials, in vaccines and gene therapy, and they may be 
incorporated into probiotic preparations to combat urogenetical tract infections and 
pulmonary immunotherapy. Gemini surfactants are effective potential transfection 
agents for non-viral gene therapy. Ionic liquids act as secondary surfactants and the 
use of surfactant/ionic liquid systems should be explored to build specific properties 
in the organized medium, and to explore pharmaceutical applications of traditional, 
biosurfactant and Gemini surfactants.
Keywords: Surfactants, biosurfactants, Gemini surfactants, gene therapy, 
pharmaceutical applications, antimicrobial activity.
1 INTRODUCTION
Surface-active agents (usually referred as surfactants, synthetic and bio-based) are active at interfaces and possess both polar (hydrophilic) and non-polar (hydrophobic) characteristics in the same molecule. The 
hydrophobic part is referred to as the head group and the hydrophobic part as 
the tail (Corrigan and Healy, 2006); Kjellin and Johansson, 2010; Monsteqszia 
and Haqqueniq, 2012; Schramm et al., 2003) (Fig. 1). 
For pharmaceutical products poorly soluble in water, the use of surfactants 
becomes inevitable to reduce the interfacial tension between the medium and 
the drug and to increase solubility of drugs. In drinks, surfactants are used 
as solubilizers to dissolve herbal medicinal materials, Vitamin E and other 
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Figure 1: Schematic representation of a surfactant.
oil ingredients. Rectovaginal and urethral surfacants increase the rate of 
percutaneous absorption and increase the solubility of medicinal materials in 
oil- and fat-based materials. Surfactants used in dental, oral, sublingual (under 
tongue) to form ointments, creams, gels, patches, tapes, and liquids, as well as 
dissolve, disperse, emulsify, and solubilize medicinal ingredients were found 
safe and ingestible.
Depending on the nature of the polar group, surfactants can be classified 
into four groups: cationic, anionic, zwitterionic and non-ionic. Scientists 
reported a systematic in vitro evaluation of the microbicidal, antiviral and 
contraceptive potential of cationic, anionic, zwitterionic, and non-ionic 
surfactants (Vieira et al., 2008). Cationic surfactants have a positive charge 
on their polar head group while anionic surfactants have a negative charge on 
their polar head group (Hait and Moulik, 2002). Zwitterionic surfactants have 
the potential to have both positive and negative charges, depending on the 
environment in which they are placed. Non-ionic surfactants have no charge 
on their head group. Generally, surfactants market is considered fragmented, 
however, few major players include AkzoNobel N.V. (The Netherlands), 
BASF SE (Germany), Henkel (Germany), P&G Chemicals (U.S.), Stepan 
Company (U.S.), The Dow Chemical Company (U.S.), and Croda, Stepan, 
Huntsman, ICI/Uniqema/Mona (U.K). Examples of surfactants that are used 
in pharmaceutical formulation are as follows:
1.1 Anionic surfactants
They carry negative charge in hydrophilic part. Examples of anionic surfactants 
include (a) carboxylates: alkyl carboxylates-fatty acid salts; carboxylate fluoro 
surfactants, (b) sulfates: alkyl sulfates (e.g., sodium lauryl sulfate); alkyl ether 
sulfates (e.g., sodium laureth sulfate), (c) sulfonates: docusates (e.g., dioctyl 
sodium sulfosuccinate); alkyl benzene sulfonates, (d) phosphate esters: alkyl 
aryl ether phosphates; alkyl ether phosphates. Sodium lauryl sulphate BP (a 
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 is used pharmaceutically as a preoperative skin cleaner, having bacteriostatic 
action against gram-positive bacteria, and also in medicated shampoos 
(Fig. 2). Branched alkyl sulphate is other example of anionic surfactants 
(Fig. 3).
1.3 Zwitterionic(amphoteric) surfactants 
They can be anionic (negatively charged), cationic (positively charged) or non-
ionic (no charge) in solution, depending on the acidity or pH of the water. 
These surfactants are very mild and have excellent dermatological properties. 
Both +ve and –ve charges may be present on the surface active portion. 
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The surface active portion bears a +ve charge, for example RN+H
3
Cl-(salt of a 




Cl-(quaternary ammonium chloride also known 
as quats). The quaternary ammonium and pyridinium cationic surfactants have 
bactericidal activity against a wide range of gram-positive and some gram-
negative organisms. They may be used on the skin, especially in the cleaning 
of wounds. Spermicidal jellies also contain quaternary ammonium salts. Ester-
quats are most common type of cationic surfactants in which ester bond is 
introduced (Fig. 4).
Non-ionic surfactants
The non-ionic surfactant can be classified as polyol esters, polyoxyethylene 
esters, poloxamers. polyol esters includes glycol and glycerol esters and 
sorbitan derivatives. Fatty acid esters of sorbitan (generally referred to as 
Spans) and their ethoxylated derivatives (generally referred to as Tweens) are 
perhaps one of the most commonly used non-ionics. 
Some examples are given below:
Sorbitan monolaurate  – Span 20
Sorbitan monopalmitate   – Span 40
Sorbitan monostearate  – Span 60
Sorbitan mono-oleate  – Span 80
Sorbitan tristearate  – Span 65
Sorbitan trioleate  – Span 8
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Some examples of Tween surfactants are given below.
Polyoxyethylene (20) sorbitan monolaurate – Tween 20
Polyoxyethylene (20) sorbitan monopalmitate – Tween 40
Polyoxyethylene (20) sorbitan monostearate – Tween 60
Polyoxyethylene (20) sorbitan mono-oleate – Tween 80
Polyoxyethylene (20) sorbitan tristearate – Tween 65
Polyoxyethylene (20) sorbitan tri-oleate  – Tween 85
The most commonly used non-ionic surfactants are ethers of fatty alcohols 
(Zhang et al., 2009). The Sorbitan esters are insoluble in water, but soluble 
in most organic solvents (low hydrophile–lipophile balance (HLB) value and 
are used as water-in-oil emulsifiers and as wetting agents. The ethoxylated 
products are generally soluble in water and have relatively high HLB numbers 
((greater than about 12). The nonionic surfactants products mainly serve as 
emulsifier, wetter, solubilizer and dispersant in pharmaceutical industry. As 
gelling agent and foaming agent, they are used in the manufacture of several 
forms of drugs such as emulsion, cream, suppository, tablet and capsule etc. 
The most frequently used surfactants are Polsorbate 20 and Polysorbate 80 and 
Poloxamer 188 in a concentration range between 0.001% and 0.1%. 
Poloxamers are synthetic block copolymers of hydrophilic poly(oxyethylene) 















)) and the 
subscripts m and n denote chain lengths. They are supplied commercially as 
Pluronics and are labelled using the Pluronic grid, for example as F127 or 
L62, where the letter indicates the physical state (F, P or L, denoting solid, 
paste or liquid, respectively). The last digit of this number is approximately 
one-tenth of the weight percentage of poly (oxyethylene); the first one (or 
two digits in a three-digit number) multiplied by 300 gives a rough estimate 
of the molecular weight of the hydrophobe (Attwood and Florence (2012). 
Poloxamers (188, 407, 338, 184), poloxamine (304, 904, 908). Other examples 
include: Polyoxyethylene 15 hydroxystearate - Solutol HS15; Polyoxyethylene 
alkyl ethers – Brij; Polyoxyethylene stearates – Myrj; Polyoxyethylene castor 
oil derivatives - Cremophor EL, ELP, RH40 (Niazi, 2004; Rowe et al., 2006). 
Surfactants have been employed as permeation enhancer in transdermal 
drug delivery of various drugs (Som et al., 2012). Moreover, biological 
surfactants perform a vital role in the metabolic processes of living organisms. 
For instance, the pathological effects of sucrose like dental cavities and also 
higher caloric contents have led to the use of certain surfactants e.g. the non-
ionic sorbitol as sugar substitutes in some confection. Surfactants applications 
include artificial implants, gene transfection, biomembranes, ophthalmology, 
and pharmaceuticals (Abraham, 2003). 
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Nonionic sufactants are most useful for humans. In the United States, the most 
commonly used vaginal spermicide is the neutral agent nonoxynol-9. However, 
octoxynol is also fully approved by the FDA. In other parts of the world, the 
surfactants benzalkonium chloride (cationic) and docusate sodium (anionic) 
are also used for contraception (Kirkman and Chantler, 1993). 
1.5 Drugs as surfactants
Many drugs have surface-active properties including the antihistamines and 
the tricyclic depressants (Florence and Attwood, 2006; Attwood and Florence, 
2012). Diazepam was found to be the most surface active substance in aqueous 
solutions, chlorpromazine was less active and the lowest activity was found for 
haloperidol (Pawelek et al., 1976). 
1.6 Aerosolized surfactants
Surfactant replacement therapy has been the core of treatment for preterm 
infants with respiratory distress syndrome for more than twenty years. 
Aerosolized surfactants for neonatal respiratory distress syndrome may 
prevent the need for endotracheal intubation (Mazela et al., 2007). Noninvasive 
ventilation has led to novel approaches of administration (Gupta and Donn, 
2012). The recent development of vibrating membrane nebulizers coupled 
with appropriate positioning of the interface device indicated that efficient 
delivery of aerosolized surfactant is a realistic goal in infants (Jane Pillow and 
Minocchieri, 2012). AEROSURF® is a drug-device product that consists of the 
entire technology system for the delivery of aerosolized surfactant to premature 
infants for respiratory distress syndrome: KL4 Surfactant, Capillary Aerosol 
Generator, and a proprietary nCPAP compatible patient interface (http://www.
discoverylabs.com/aerosurf.php). 
1.7 Silicon surfactants
Silicone surfactants are becoming increasingly important in the pharmaceutical 
industry. Silicones (more accurately called polysiloxanes) are mixed inorganic-




, where R is organic 
groups such as methyl, ethyl, and phenyl. The polydimethylsiloxanes, compared 
to other polymers, are very permeable to the diffusion of active drugs. The 
hydrophobic and amorphous low-density properties of polydimethylsiloxanes 
have also made it the material of choice in the drug delivery implant called 
Norplant. The preparation, properties and application of carbohydrate-modified 
silicone surfactants such as glucosamide-containing and glycoside-containing 
silicone surfactants have been reported (Han et al., 2012). 
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1.8 Fluorinated Surfactants
Hemifluorinated surfactants could potentially aid in the development of new 
strategies for contraception (Rajni, 2010). 
1.9 Surfactant proteins
The role of the surfactant system for the development of the human lung is 
known to be essential. Pulmonary surfactant is a complex mixture of lipids 
and proteins that regulates dynamically the alveolar surface tension. There 
are four main surfactant proteins, known as surfactant protein (SP)-A, B, 
C, and D. SP-A and D are hydrophilic while SP-B and C are hydrophobic 
(Goldmann et al., 2009). SP-A, the most prominent among four proteins 
in the pulmonary surfactant-system, is expressed by alveolar epithelial 
cells type II as well as by a portion of non small cell lung carcinomas. 
Surfactant proteins fulfil several different functions in the human body. The 
first vaginal microbicide nonoxynol-9 acted as a surfactant (Weber et al., 
2005). Surfactant protein SP-A is an essential component of the host-defence 
system in the lung as well as in vagina (MacNeill et al., 2004). Surfactant 
proteins B (SP-B) and C (SP-C) are well-documented genetic disorders. 
Surfactant proteins B and C (SP-B and SP-C) are small hydrophobic proteins 
of pulmonary surfactant that are essential for lung function. Deficiency or 
abnormal protein expression due to SP-B and SP-C gene mutations has been 
linked to various acute and chronic lung diseases (Beers and Mulugeta, 
2006). Surfacant protein-D is present throughout the female genital tract 
(Leth-Larsen et al., 2004). 
1.10 Pulmonary surfactant
Pulmonary surfactant is a surface-active lipoprotein complex (phospho-
lipoprotein) formed by type II alveolar cells. The proteins and lipids that 
comprise the surfactant have both a hydrophilic region and a hydrophobic 
region. Synthetic pulmonary surfactants include: Exosurf - a mixture of 
DPPC with hexadecanol and tyloxapol added as spreading agents; Pumactant 
(Artificial Lung Expanding Compound or ALEC) - a mixture of DPPC and 
PG; KL-4 - composed of DPPC, palmitoyl-oleoyl phosphatidylglycerol, and 
palmitic acid, combined with a 21 amino acid synthetic peptide that mimics 
the structural characteristics of SP-B; Venticute - DPPC, PG, palmitic acid and 
recombinant SP-C. Animal derived surfactants include: Alveofact - extracted 
from cow lung lavage fluid; Curosurf - extracted from material derived from 
minced pig lung; Infasurf - extracted from calf lung lavage fluid; Survanta 
- extracted from minced cow lung with additional DPPC, palmitic acid and 
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tripalmitin. Exosurf, Curosurf, Infasurf, and Survanta are the surfactants 
currently FDA approved for use in the U.S (Taeush, 2002). 
Surfactant proteins have also been discovered in non-pulmonary tissues 
such as skin epidermis (Mo et al., 2007), nasal mucus membrane (Vaandrager 
and van Golde, 2000; Woodworth et al., 2007), and tear fluid (Brauer 2007a; 
Brauer 2007b). Peptide-containing surfactant provides clinical efficacy in the 
treatment of respiratory distress syndrome and offers promise for treating 
other lung diseases in infancy (Donn and Sinha, 2008; Halliday, 2008; Mazela 
et al., 2006). 
Surfactant proteins are an important part of the human immune system 
for fighting bacterial pathogens. It has now shown that the surfactant 
proteins also exist in pathogenic bacteria (Bräuer et al., 2013). Researchers 
have now shown these proteins to exist in two pathogenic types of bacteria, 
staphylococcus aureus and pseudomonas aeruginosa, which are both germs 
that can cause severe infections of the lungs and other organs. Latherin, a 
surface active protein from horse sweat causes the foaming of a sweating 
horse, particularly where harness and saddle rub. Its function is to wet 
the hair and facilitate the rapid translocation of sweat water from the skin 
to the surface of the pelt to allow evaporative cooling. The recombinant 
form of the protein is also highly surface active. It is also produced in the 
salivary glands of horses, and that it is also made by zebras, onagers and 
wild asses.
1.11 Surfactant Polymers
The general classification of polymeric surfactants (homopolymers, block and 
graft copolymers), their solution properties, stabilization of suspensions and 
nanoemulsions using INUTEC®SP1 have been reported (Tadros, 2009). General 
applications of polymeric surfactants include pharmaceuticals and personal 
care products. Polymeric surfactants offer many performance advantages over 
traditional surfactants, especially in the challenging parental administration of 
drugs, which can be prone to physical instability (Tadros, 2009). 
Hydroxypropyl methylcellulose is a non-ionic polymer extensively 
used in Pharmaceutical formulations. The polymeric surfactant is useful for 
stabilising the interface in emulsions or dispersions (Michael, 2010). Many 
useful properties of polyelectrolyte surfactant complexes come from the 
highly ordered structures of surfactant self-assembly inside the polyelectrolyte 
aggregate and polyelectrolyte surfactant complexation may be helpful for 
pharmaceutical and biological applications. Researchers have demonstrated the 
role of hydroxypropyl methylcellulose-anionic surfactant interactions during 
the dissolution of non-ionic hydrophilic polymer based solid dispersions and 
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have highlighted the potential relevance of this to a fuller understanding of 
drug solubilisation/stabilisation in vivo (Qi et al., 2013). Inutec SP1 (Fig. 5 
and Fig. 6) is a non-ionic, polymeric-based surfactant system derived from 
chicory inulin (http://www.beneo-bbc.com/Our-Products/INUTECA). It is a 
graft copolymer based on a naturally occurring polysaccharide, namely inulin 
(polyfructose) that has been hydrophobically modified by introducing several 
alkyl groups on the linear polyfructose chain (Van den Mooter et al., 2006). 
The superior dissolution behaviour of the drugs from Inutec® SP1-based solid 
dispersions could be ascribed to its surface-active nature (Srinarong et al., 
2011). The spherically agglomerates crystals of felodipine with Inutec SP1 
were reported for enhanced dissolution rate properties of this drug by spherical 
crystallization technique (Tapas et al., 2009). 
The dissolution rate of etodolac at pH 1.2 and 6.8 was found improved 
containing polymeric surfactant inutec-etodolac system compared to that of the 
pure drug and physical mixtures. Inutec-based coevaporate based formulation 
of etodolac chewable tablets showed significantly higher mean C
max
 and shorter 
mean T
max
 (about 2 h earlier) and about 1.32-fold higher mean AUC
0–24
 values 
for the F3 chewable tablets compared to etodolac-filled capsules (Ibrahim et 
al., 2010). 
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Inulin backbone
Alkyl chains
Figure 6: Schematic representation of INUTEC®SP1 polymeric surfactant.
1.12 Alkylpolyglucoside surfactant 
The alkyl polyglucosides are derived from reacting corn starch with a fatty 
alcohol to produce highly biodegradable new surfactants. Low ethoxylated 
monoglycerides - like PEG-7 cocoate - and alkyl polyglucosides - like Plantaren 
(decyl glucoside), Plantapon LGC Sorb (sodium lauryl glucose carboxylate), 
and Plantasol CCG (caprylyl capryl glucoside) are known. PEG-7 glyceryl 
cocoate is a non-ionic, low ethoxylated monoglyceride that can behave as an skin 
conditioner. A comparative study of the ocular irritation potential of various alkyl 
polyglucoside surfactants showed a good correlation between the proportion of C
10
 
alkyl polyglucoside and the eye irritation potential Q score. Alkyl polyglucoside 
bases could be considered as preferential option in drug compounding related to 
the conventional ones (Jaksic et al. 2012). Results indicated a good safety profile 
of alkylpolyglucoside surfactant (Savić et al., 2007). 
1.13 Ionic liquid surfactants 
Ionic liquids as surfactants are easier to incorporate into formulations 
(Smirnova and Safonova, 2010). Microemulsions comprising an ionic liquid 
as surfactant were reported (Zech et al., 2009). The effect of ionic liquids 
addition on surfactant solution can be regarded as the comprehensive effects 
of inorganic salt, cosurfactant, and cosolvent on surfactant solution (Shang et 
al., 2010). When ionic liquids are used in small amounts (say less than 1 wt 
%), they behave more like “greener” surfactants. Further, ionic liquids look 
similar to amphoteric surfactants. 
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Mixed micelles containing more than one type of surfactants are of great 
importance from the viewpoint of pharmaceutical research. Ionic liquids can 
be added as cosurfactants or hydrotropes to aqueous solutions of common 
surfactants, thus affecting the surface activity and the critical micelle 
concentration of these solutions. Properties of these mixed micelles often 
strongly depend on the surfactant/ ionic liquids ratio and on the nature of 
the surfactant head group. . The unique role of ionic liquids in changing 
properties of aqueous surfactant systems has also been demonstrated (Behera 
et al., 2009; Behera and Pandey, 2009; Brown et al., 2011; Comelles, 2012). A 
series of anionic surfactant ionic liquids has been synthesized based on organic 
surfactant anions and 1-butyl-3-methyl-imidazolium cations (Brown et al., 
2012a). Ionic liquid [bmin][BF
4
] favoured early formation of micelle in case 
of cationic and anionic aqueous surfactant solutions, but slightly prolonged 
micelle formation in the case of neutral aqueous surfactant solution. However, 
for curcumin IL [bmin][BF
4
] favored strong association (7-fold increase) with 
neutral surfactant solution, marginally supported association with anionic 
surfactant solution and discouraged (∼2-fold decrease) association with 
cationic surfactant solution.
1.14 Magnetic ionic liquid surfactants 
Magnetic fields may be used to tune the behaviour of the surfactant at the air-water 
interface. Mixing conventional cationic surfactants with iron salt results in the 
exchange of the original anion with the iron-containing ion. The resulting ionic 
liquid surfactant responds to a magnetic field. (Fig. 7). The standard surfactant, 
however, has a bromide ion (Br-) as counter ion (a), while the modified one has 
the iron-containing ion FeCl
3
Br- (b). Two other surfactants, 1-decyl-3-methyl 





Br- as counter ions respectively (Brown, 2012b). 
The potential applications of magnetic surfactants are not yet explored.
1.15 Surfactants from renewable resources
There are many advantages of using natural-based products as raw materials for 
surfactant applications compared to petroleum-based raw materials. Surfactants 
based on natural starting materials can often be made more biodegradable, less 
toxic and less allergenic. Renewable sources of hydrophilic groups include 
carbohydrates, proteins, amino acids and lactic acid, and sources of the 
hydrophobic moiety are steroids, monoterpenes, rosin acids, fatty acids and 
long chain alkyl groups, as well as aromatic compounds (Kjellin and Johansson, 
2010). Rosin is reputed as green petroleum because it is renewable, not 
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expensive, and environmental friendly. Rosin-based surfactants are commonly 
used as antibacterial and antifungal agents (Rao, 2012). 
1.16 Sugar-based surfactants 
Natural surfactants based on plant
Carbohydrate-based surfactants, being based on plant-derived chemicals, use 
renewable resources, are readily biodegradable and are non toxic. Structures of 
three common carbohydrate-based surfactants are shown below (Fig. 8):
A few of the currently available carbohydrate-based surfactants include: 
Alkyl polyglucosides - Triton APGs (Union Carbide), Plantcare (Cognis/
Henkel), Lauryl glucoside, Monatrope (ICI/Uniqema); Sorbitan esters - 
Crills (Croda) and Spans (ICI/Uniqema): Sucrose esters - Crodestas (Croda). 
Alkylpolyglucoside surfactants are synthesized by reacting corn starch glucose 
with a coconut oil derived alcohol by the Fischer synthesis. The amphiphilic 
dextran derivatives have been shown to become convenient drug vehicles 
(Rotureau et al., 2005; Rotureau et al., 2006a; Rotureau et al., 2006b; Rotureau 
et al., 2007). 
Sugar-based surfactants are more stable and sustainable (Ruiz, 2012). 
Formulations of the alkyl polyglycosides are used in hair and skin care. On 
an ingredient label they are usually identified as a variety of “glucosides,” 
for example decyl glucoside or lauryl glucoside. Sugar-based surfactants 
complement alkyl polyglycosides that are already on the market. A new 
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family of surfactants based on simple sugars and natural oils hold promise 
to clean without a long list of environmental side effects (Foley et al., 2011). 
Sugar-based surfactants such as trehalose fatty acid ester, Plantacare 818 and 
Plantacare 2000 are suitable alternatives to polysorbates in the applied field of 
low concentration protein formulations (Schiefelbein et al., 2010). 
1.17 Silicone surfactants
Silicones (more accurately called polymerized siloxanes or polysiloxanes) are 





R is organic groups such as methyl, ethyl, and phenyl (Hill, 2002). The demand 
for environmental-friendly surfactants is becoming greater. A composition 
comprising at least one sugar silicone surfactant and at least one oil-soluble 
polar modified polymer have pharmacological and/or cosmetic applicability 
(Bui, 2011). There are of course lots of modern surfactants, but products such 
as sodium laureth sulphate can, on sensitive skin, cause problems. Amino acid-
based surfactants on the other hand have been shown to be skin-friendly even 
when used on a daily basis.
1.18 Natural surfactants/biosurfactants
Nature own surfactant include polar lipids, bile salts, phospholipids lecithin, 
and certain fatty acids and their derivatives. Phospholipids are the major 
components of synthetic lung surfactant, used in the treatment of acute and 
neonatal distress syndrome (Acosta et al., 2009) and of liposomes which are 
common delivery vehicles (Immordino et al., 2006; Shailesh et al., 2009).
Calfactant, also known as Infasurf is an intratracheal suspension derived 
from the natural surfactant in calf lungs. This lung surfactant is essential 
for effective ventilation as it modifies alveolar surface tension. Neonatal 
respiratory distress is caused by a lung surfactant deficiency (Tadros, 
2005).
Natural surfactants include the anionic alkyl polyglucosides (decyl, lauryl, 
and octyl), which are made from fatty alcohols from coconut or palm and 
glucose from corn starch. Other natural surfactants include lauryl glucose 
carboxylate which provides added foaming ability. Glutamate surfactants such 
as disodium cocoyl glutamate, sodium cocoyl glutamate are mild and made 
from amino acids. Commonly employed surfactants in pharmaceutical products 
include: β-dodecyl maltoside (an alkyl polyglycoside), sucrose-6-monolaurin 
(a saccharide fatty acid ester), polysorbate (ethoxylated sorbitan-oleic acid 
ester), 1-monolaurin (a monoacylglycerol), α-tocopheryl polyethylene glycol 
succinate) 
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1.19 Biosurfactants
Biosurfactants are surfaceactive compounds from biological sources, usually 
extracellular, produced by bacteria, yeast or fungi (Sekhon, 2006; Sen, 
2010; Xu et al., 2011). Biosurfactants are derived either through the route of 
microbial fermentations or through the in-vitro enzyme catalyzed reactions. 
Biosurfactants can be classified by their chemical composition, molecular 
weight and their origin (Okoliegbe and Agarry, 2012). They are grouped 
into three categories of origin: microbially derived surfactants [glycolipids, 
lipopeptides and phospholipids], animal-derived surfactants [lecithin] and plant-
derived biosurfactants [soy protein]. Based on composition, biosurfactants can 
be divided into different categories: Phospholipid (T. thiooxidans); Fatty acids 
(Hare corynebacterium); Lipopeptide and lipoprotein (Bacillus subtilis & 
Bacillus licheniformis); Polymer (LPS) (B calcium acinetobacter); Glycolipid: 
Trehalose fat Paraffin (arthrobacter & corynebacterium); Rhamnolipid 
(pseudomonas aeruginosa); Sophorolipid (Xie Candida lipolytica); Fiber two 
glycolipids (Hung Ping rhodococcus). In addition, biosurfactants product 
categories include: Methyl ether sulfonates, Alkyl polyglucosides, Sorbitan 
esters, Sucrose esters, Fatty acid N-methylglucimides, Methyl glucoside 
esters, Anionic alkyl polyglucosides derivatives, Alkyl polypentosides Most 
biosurfactants are either anionic or neutral. Biosurfactants offer the possibility 
of replacing chemical surfactants (Marchant and Banat, 2012a; Marchant and 
Banat, 2012b)). 
Biosurfactants have a wide range of applications in pharmaceutical fields 
(Mukherjee et al., 2006). Several biosurfactants have been reported to possess 
antifungal, antibacterial, antiviral, antimycoplasma, immunomodulatory and 
antitumor activities (Desai et al., 2008; Gharaei-Fathabad, 2011; Krasowska, 
2010; Mukherjee et al., 2006; Muthusamy et al., 2008; Okoliegbe and Agarry, 
2012; Rodrigues et al., 2006; Rodrigues and Teixeira, 2010; Seydlová and 
Svobodová 2008; Sriram et al., 2011; Zhao et al., 2010). However, their practical 
use as therapeutic drugs is to some extent limited by their hemolytic activity 
and cytotoxicity towards normal animal cell lines (Nasrollahi1 et al., 2012; 
Rodrigues and Teixeira, 2010a; Rodrigues and Teixeira, 2010a; Rivardo et al., 
2009). Currently, applications of biosurfactant-based microbubbles provide a 
promising therapeutic approach for targeted treatments (Xu et al., 2011). 
Biosurfactants inhibited the adhesion of pathogenic organisms to solid 
surfaces or to infection sites (Rodrigues et al., 2006). Microbial extracellular 
glycolipids use as novel reagents for the treatment of cancer cells has been 
reported (Okoliegbe and Agarry, 2012). As immunological adjuvants, bacterial 
lipopeptides when mixed with conventional antigens improved the humoral 
humane response (Gharaei-Fathabad, 2011; Rivardo et al., 2009). Other 
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Scheme 1. The structure of a typical surfactant and a gemini surfactant.
applications of biosurfactant include gene delivery and as agents for stimulating 
stem fibroblast metabolism (Krishnaswamy et al., 2008).
Some advantages of biosurfactants are biodegradability, low toxicity, 
better surface and interfacial activity while some of its limitations are inability 
to scale up the production process and patent rights (Fakruddin, 2012). 
1.20 Gemini surfactants
Gemini surfactants (GS) are comprised of two surfactant monomers chemically 
bonded at or near the headgroups by a rigid or flexible spacer (Scheme 1) 
(Ikeda, 2003; Sekhon, 2004; Wang et al., 2009; Zana, 1996). In comparison 
to their corresponding monomer counterparts, geminis are three orders more 
surface active, have better wetting properties, and typically exhibit much lower 
critical micelle concentration strong dependence on spacer structure, special 
aggregate morphology, and strong hydrophobic microdomain (Menger and 
Littau, 1991; Menger and Littau, 1993; Menger and Keiper, 2000). 
Cationic gemini surfactants exhibit much higher surface activity than their 
monomeric counterparts. Rapid synthesis of Gemini surfactants (C (12)-C(2)-
C(12) and C(14)-C(6)-C(14)) by microwave heating has been reported. The 
synthesis yields of C(12)-C(2)-C(12) obtained using the 915-MHz equipment 
were three to four times higher than those obtained using the conventional 
heating method (Horikoshi et al., 2013). Amino acid-substituted gemini 
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surfactants perform better compared to the surfactants possessing unsubstituted 
spacers (Yang et al., 2010). Different lyophilization strategies and analytical 
methods have been established to develop and examine the physiochemical 
stability of gemini surfactant-based lipoplex (Mohammed Saeid, 2012a). 
GS are of special interest as drug vehicles and gene therapy. GS are viewed as 
effective potential transfection agents for non-viral gene therapy and one example 
of which is Lipofectamine Plus (Invitrogen) (Wettig et al., 2007; Wettig et al., 
2009). In addition, GS can be synthesized fairly easily and at low cost, therefore 
making them advantageous from a pharmaceutical industrial manufacturing and 
economical perspective (Zana and Xia, 2004). Cationic serine-based GSs have 
enhanced interfacial properties and low cytotoxicities, offering potential use in 
technical and biological applications (Silva et al., 2013). 
Lyophilization significantly improved the physical stability of gemini 
surfactant-based lipoplexes compared to liquid formulations. Lyophilization 
also improved the transfection efficiency of the lipoplexes (Mohammed-Saeid 
et al., 2012b). The inclusion of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
in gemini surfactant-based lipoplexes significantly increased the transfection 
efficiency 108. Gemini surfactant structures capable of inducing a wide variety 
of polymorphic structures demonstrated higher transfection efficiencies (Wettig 
et al., 2008). The hemolytic activity of arginine-based gemini surfactants 
increased with the aliphatic alkyl chain lengths of the hydrophobic tail (Mitjans 
et al., 2003). Geminis have a superior ability for dispersing CNTs compared to 
other pharmaceutical surfactants. Nimodipine-loaded egg phosphatidylcholine-
sodium glycocholate mixed micelles improve the water solubility of nimodipine, 
thus making it to be more applicable for clinical use (Song et al., 2012a). 
Glycyl-lysine substitution in the gemini spacer conferred to the P/12-7NGK-
12/L nanoparticles the ability to escape efficiently from clathrin-mediated 
endosomes compared to the parent gemini surfactant (Singh et al., 2012). 
Gemini ester quat surfactants incorporate more easily into the lipid bilayer of 
the erythrocyte membrane and affect its properties to a greater extent (Łuczyński 
et al., 2013). Researchers reported heparin determination at the nanogram level 
in pharmaceutical samples using gemini surfactant (dodecyl polyoxyethylene 
ether biquaternary ammonium salt. It was found that gemini surfactant reacted 
with anionic heparin to form an ion-association complex (Song et al., 2012b). 
1.21 Aquatic toxicity of surfactants
After use, however, surfactants often end up in our environment. Most 
surfactants are more or less toxic to aquatic organisms due to their surface 
activity which will react with the biological membranes of the organisms. 
Generally an increase of the chain length in the range of 10 to 16, leads to 
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an increase in toxicity to aquatic organisms. Aquatic toxicity is an important 
characteristic of all surfactants (Ardelean et al., 2011; Persson, 2012). 
1.22 pH-sensitive gemini surfactants
pH-sensitive surfactants are often added as a secondary surfactant to enhance 
performance properties, including solubility, foaming, and mildness to the skin 
or to the eyes. In addition, pH-sensitive surfactants may be used effectively in 
novel applications where pH variations can be utilized to control drug release 
and targeted gene delivery. The lysine-based surfactants showed concentration-
dependent and pH-sensitive hemolytic activity, with a significant increase in 
the hemolysis at pH 5.4 (Nogueira et al., 2011). 
The possibility of using pH-sensitive surfactants for endosome disruption 
could hold great promise for intracellular drug delivery systems in future 
therapeutic applications. The development of biocompatible lysine-based 
surfactants conjugates as potential drug delivery systems for pharmaceutical 
applications is under investigation by various workers. Amino-substituted gemini 
surfactants are potential components for developing non-viral nanoparticles 
with enhanced gene delivery for targeting diseases affecting the skin. In this 
context, gemini nanoparticles were formulated from plasmid DNA, the lipid 
(dioleoylphosphatidylethanolamine) and surfactants, where the surfactant 
components are novel pH-sensitive GS derivatives based on the m-7-m (alkyl 
chain–spacer–alkyl chain, m-s-m) unsubstituted base structure. The incorporation 
of a pH-active amine group within the spacer of the GSs significantly enhanced 
transfection efficiency in keratinocytes (Donkuru et al., 2012). 
2 ReGUlATORy ASPeCTS OF SURFACTANTS
The use of surfactants becomes inevitable to reduce the interfacial tension 
between the medium and the drug. FDA guidelines state that the use of 
surfactants in a dissolution medium in drug development requires justification. 
Safety has always been the most important requirement and the most studied 
when dealing with pharmaceutical drugs. In the United States, the food and drug 
administration (FDA) has published listings in the code of federal regulations 
(CFR) for GRAS substances that are generally recognized as safe (U.S. Food and 
Drug Administration). In general, nonclinical and clinical studies are required to 
demonstrate the safety of a new surfactant before use. The US FDA has published 
a guidance document for industry on the conduct of nonclinical studies for the 
safety evaluation of new pharmaceutical excipients (U.S. Department of Health 
and Human Services). This guidance not only provides the types of toxicity data to 
be used in determining whether a potential new excipient is safe, but also describes 
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the safety evaluations for excipients proposed. The document also depicts testing 
strategies for pharmaceuticals proposed for short -term, intermediate, and long 
-term use (U.S. Department of Health and Human Services). More importantly, 
this guidance highlights the importance of performing risk-benefit assessments 
on proposed new excipients in the drug products while establishing permissible 
and safe limits for the excipients. It is often possible to assess the toxicology 
of an excipient in a relatively efficient manner. Existing human data for some 
excipients can substitute for certain nonclinical safety data. In addition, an 
excipient with documented prior human exposure under circumstances relevant 
to the proposed use may not require evaluation with a full battery of toxicology 
studies (U.S. Department of Health and Human Services). 
3 CONClUSIONS AND PeRSPeCTIveS
Modern surfactants have to meet market requirements in mildness and naturalness. 
The synthetic surfactants have drivers such as low price, easy availability, and 
broadened application areas, whereas drivers for bio-based surfactants are their 
ecological benefits, availability of a wide range of substrates, increasing awareness 
towards eco-friendly products. Surfactants are commonly used in upstream and 
downstream processing and drug formulation. Surfactants of general use increase 
i) the percutaneous absorption and solubility of medicines and pharmaceutical 
agents, ii) increase the hydrophilicity of oil bases used in ointments and patches. 
Surfactants are commonly used in pharmaceutical protein formulations to 
compete for interfacs that might cause unfolding and aggregation of the API. The 
application of non-ionic surfactants is found ubiquitary in protein formulations. 
Natural surfactants are derived from the carbohydrates sorbitol, sucrose, glucose 
and from plant oils such as coconut or palm kernel. Lung surfactant contains 
phospholipids and makes it easier for oxygen to penetrate the lung surface lining 
and move into the blood. Peptide-containing surfactant provides clinical efficacy 
in the treatment of respiratory distress syndrome and offers promise for treating 
other lung diseases in infancy. Biosurfactants offer the possibility of replacing 
chemical surfactants. They are useful in combating many diseases and act i) as 
therapeutic agents due to their antibacterial, antifungal and antiviral activities, ii 
) as anti-adhesive agents against several pathogens.
Gemini surfactant (GS) molecules use as drug delivery systems is one 
of the more active areas of research. GS are used as transfection agents for 
DNA delivery. Lyophilization significantly improved the physical stability of 
GS-based lipoplexes compared to liquid formulations. Lyophilization also 
improved the transfection efficiency of the lipoplexes. Geminis have shown 
efficiency in skincare, antibacterial property and are considered as a effective 
potential transfection agents for non-viral gene therapy. There are substantial 
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differences in the micellization tendencies of mixtures of surfactants as compared 
with the single pure species. Thus, it is of great importance to evaluate and 
understand the interactions of Gemini surfactants with common surfactants 
typically found in pharmaceutical applications. pH-sensitive surfactants for 
endosome disruption should be further explored for intracellular drug delivery 
systems in future therapeutic applications.
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